Oscar Health (NYSE:OSCR) Director Sells $748,592.80 in Stock

Posted by Stanley Muller on Jun 7th, 2026

Oscar Health, Inc. (NYSE:OSCR – Get Free Report) Director Mario Schlosser sold 34,120 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total value of $748,592.80. Following the sale, the director directly owned 480,866 shares in the company, valued at $10,550,200.04. This trade represents a 6.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Stock Performance

Shares of OSCR opened at $24.59 on Friday. The stock’s 50-day simple moving average is $18.39 and its 200 day simple moving average is $16.06. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of -41.68, a price-to-earnings-growth ratio of 1.71 and a beta of 2.37. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11. Oscar Health, Inc. has a 52-week low of $10.69 and a 52-week high of $25.58.

Oscar Health (NYSE:OSCR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. The business had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The firm’s quarterly revenue was up 52.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 EPS. Research analysts forecast that Oscar Health, Inc. will post 0.47 EPS for the current fiscal year.

Key Oscar Health News

Here are the key news stories impacting Oscar Health this week:

Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold”, easing bearish sentiment even though its $20 target remains below the current share price. Zacks.com
Positive Sentiment: Oscar Health’s recent earnings showed a major EPS beat, which supports the stock’s fundamental story despite revenue coming in below estimates.
Neutral Sentiment: A company co-founder shifting into an advisory leadership role looks like an internal reorganization rather than a disruptive change. Oscar Health Co-Founder Shifts to Advisory Leadership Role
Neutral Sentiment: Multiple insiders, including CFO Richard Scott Blackley and CAO Victoria Baltrus, sold shares under pre-planned 10b5-1 programs to cover tax obligations on vested equity awards, which is less concerning than discretionary selling.
Negative Sentiment: Director Mario Schlosser sold 34,120 shares, the largest insider sale in the latest batch, which may pressure sentiment even though it was pre-arranged.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. UBS Group raised their price target on Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Wells Fargo & Company set a $20.00 price target on Oscar Health and gave the company an “equal weight” rating in a report on Thursday. Raymond James Financial raised Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a report on Thursday, February 12th. Wall Street Zen cut Oscar Health from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oscar Health in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.22.

View Our Latest Analysis on Oscar Health

Hedge Funds Weigh In On Oscar Health

Institutional investors have recently modified their holdings of the company. Quarry LP increased its position in shares of Oscar Health by 439.8% during the 3rd quarter. Quarry LP now owns 1,803 shares of the company’s stock valued at $34,000 after purchasing an additional 1,469 shares during the last quarter. Tsfg LLC bought a new position in shares of Oscar Health during the 3rd quarter valued at about $38,000. Jones Financial Companies Lllp increased its position in shares of Oscar Health by 7,473.3% during the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after purchasing an additional 2,242 shares during the last quarter. Strs Ohio bought a new position in shares of Oscar Health during the 1st quarter valued at about $30,000. Finally, Fifth Third Bancorp increased its position in shares of Oscar Health by 148.7% during the 4th quarter. Fifth Third Bancorp now owns 2,363 shares of the company’s stock valued at $34,000 after purchasing an additional 1,413 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Company Profile

(Get Free Report)

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.